CTI BioPharma Corp. (CTIC) has a consensus analyst rating of Buy, based on 19 analysts covering the stock. Of those, 13 recommend buying, 6 recommend holding, and 0 recommend selling.
The analyst consensus price target for CTIC is $10.40, representing a +14.3% upside from the current price of $9.095. Price targets range from a low of $9.00 to a high of $13.00.
